Skip to main content
. Author manuscript; available in PMC: 2023 Sep 25.
Published in final edited form as: Trends Mol Med. 2022 Oct 5;28(12):1112–1127. doi: 10.1016/j.molmed.2022.09.001

Figure 6.

Figure 6.

Prevention of asthma exacerbations by omalizumab, anti-IgE. Omalizumab reduces IgE including cell-bound IgE. With reduced cell-bound IgE, mast cell activation is reduced to diminish the development of inflammation. In addition, omalizumab removes IgE from the cell surface of dendritic cells, which allows dendritic cells to produce more antiviral interferon-α when exposed to respiratory viruses.